Edition:
United States

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

1.95USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.95
Open
$1.90
Day's High
$2.00
Day's Low
$1.90
Volume
1,367,170
Avg. Vol
252,817
52-wk High
$24.00
52-wk Low
$1.65

Latest Key Developments (Source: Significant Developments)

Versartis reports Q3 loss $1.40/shr
Thursday, 26 Oct 2017 04:05pm EDT 

Oct 26 (Reuters) - Versartis Inc :Versartis reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $1.40.Q3 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.  Full Article

Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint
Thursday, 21 Sep 2017 04:30pm EDT 

Sept 21 (Reuters) - Versartis Inc :Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint.Versartis Inc - Study ‍did not meet its primary endpoint of non-inferiority.​.Versartis Inc says ‍somavaratan was well tolerated with treatment discontinuation rate lower than for genotropin arm.​.Versartis Inc - ‍No new emergent safety signals were observed in the study​.  Full Article

Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​
Monday, 7 Aug 2017 05:59pm EDT 

Aug 7 (Reuters) - Versartis Inc :Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​.  Full Article

Versartis reports Q2 loss per share $1.04
Thursday, 27 Jul 2017 04:05pm EDT 

July 27 (Reuters) - Versartis Inc :Versartis reports second quarter 2017 financial results.Q2 loss per share $1.04.Q2 earnings per share view $-0.84 -- Thomson Reuters I/B/E/S.  Full Article

Versartis Q1 loss per share $0.85
Thursday, 27 Apr 2017 04:05pm EDT 

April 27 (Reuters) - Versartis Inc ::Versartis reports first quarter 2017 financial results.Q1 loss per share $0.85.Versartis Inc - research and development (research and development) expenses for quarter ended march 31, 2017 were $22.0 million, compared to $18.2 million.Q1 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.  Full Article

Versartis reports new data on Somavaratan in growth hormone deficiency
Monday, 3 Apr 2017 07:30am EDT 

Versartis Inc : Versartis reports new data on long-acting Somavaratan in growth hormone deficiency at endo 2017 . Baseline characteristics of phase 3 velocity trial population balanced between study arms and comparable to phase 2 .Further results from vital trial in adult ghd-similar Somavaratan PK/PD data in U.S., Japanese children support using same dose in ongoing phase 3 trials.  Full Article

Versartis Q4 loss per share $0.64
Tuesday, 21 Feb 2017 04:05pm EST 

Versartis Inc : Versartis reports fourth quarter 2016 financial results . Q4 loss per share $0.64 .Q4 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article

Advent Life Sciences reports a 6.6 pct passive stake in Versartis-SEC filing
Friday, 10 Feb 2017 06:10am EST 

Versartis Inc :Advent Life Sciences Llp reports a 6.6 percent passive stake in Versartis Inc as of December 31, 2016 -sec filing.  Full Article

Versartis reports Q3 loss per share of $0.92
Thursday, 3 Nov 2016 08:31pm EDT 

Versartis Inc : Versartis reports third quarter 2016 financial results . Q3 loss per share $0.92 .Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Versartis reports Q3 loss per share of $0.92
Thursday, 3 Nov 2016 04:05pm EDT 

Versartis Inc : Versartis reports third quarter 2016 financial results . Q3 loss per share $0.92 .Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Versartis Inc Says Board Appointed Jay Shepard, CEO, To Position Of Principal Financial Officer

* VERSARTIS INC SAYS ‍ON NOV 28, 2017, BOARD APPOINTED JAY SHEPARD, CEO, TO POSITION OF PRINCIPAL FINANCIAL OFFICER, EFFECTIVE DEC 1, 2017 - SEC FILING​ Source text (http://bit.ly/2A3BTve) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)